Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study

Lee, Jin Wook; Song, Eun Mi; Jung, Sung-Ae; Jung, Sung Hoon; Kim, Kwang Woo; Koh, Seong‐Joon; Lee, Hyun Jung; Hong, Seung Wook; Park, Jin Hwa; Hwang, Sung Wook; Yang, Dan; Ye, Byong Duk; Myung, Seung‐Jae; Yang, Suk‐Kyun; Park, Sang Hyoung

doi:10.3346/jkms.2021.36.e336

Cited by 3 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Information from 16 studies and the SECURE-IBD registry were used in evaluating the risk of adverse outcomes in UC and CD patients infected with SARS-CoV-2, including 6243 UC patients and 7308 CD patients [ 18 , 23 , 33 , 34 , 36 , 38 , 40 – 49 ]. The pooled RR was 1.38 (95% CI 1.27–1.50), with no evidence of heterogeneity ( I 2 = 13%; P = 0.31; Fig.…”

Section: Resultsmentioning

confidence: 99%

Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis

Chen

Hu²,

Cheng³

et al. 2022

Int J Colorectal Dis

View full text Add to dashboard Cite

Background Between people with and without inflammatory bowel disease (IBD), there was no statistically significant difference in the probability of contracting the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, the risk of adverse outcomes in IBD patients after virus infection remains unclear. Methods Eligible studies conducted from January 1, 2020 to March 17, 2022 were obtained by searching PubMed, Embase, and Web of Science. Information was collected in tables from the included studies. Random-effects and fixed-effects models were used as measures for the pooled estimates. All data were estimated by R version 4.1.3. Results Twenty-four studies were included. The risk ratio (RR) of adverse outcomes in COVID-19 patients with IBD increased by 32% (RR 1.32; 95% CI 1.06–1.66) relative to COVID-19 patients without IBD. The RR of mortality was higher in COVID-19 patients with IBD from Europe (RR 1.72; 95% CI 1.11–2.67) than in those that were not from Europe (RR 1.00; 95% CI 0.79–1.26; χ 2 = 4.67; P = 0.03). Patients with ulcerative colitis were at higher risk of adverse outcomes after SARS-CoV-2 infection than patients with Crohn’s disease patients (RR1.38; 95% CI 1.27–1.50). The IBD drugs treatment was associated with the risk of adverse outcomes, the pooled odds ratio (OR) of mesalazine (1.79; 95% CI 1.59–2.02), immunomodulators (1.30; 95% CI 1.10–1.53), and anti-TNF (0.47; 95% CI 0.41–0.53) were assessed. Conclusion COVID-19 patients with IBD had an increased risk of adverse outcomes than those without IBD, whereas anti-TNF treatment might reduce the risk. Supplementary Information The online version contains supplementary material available at 10.1007/s00384-022-04265-w.

show abstract

Section: Resultsmentioning

confidence: 99%

Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis

Chen

Hu²,

Cheng³

et al. 2022

Int J Colorectal Dis

View full text Add to dashboard Cite

show abstract

“…Studies assessing the characteristics, evolution, and risk factors associated with severe forms of COVID-19 infection in patients with IBD have reported issues similar to those of the general population [ 7 , 8 ]. However, most of these studies are limited by the small number of patients [ 9 ]. Despite their immunosuppressed status and specific medication, IBD patients seem to develop mild forms of COVID-19 [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 Pandemic on the Quality of Life of IBD Patients

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: The COVID-19 pandemic has had a considerable impact on inflammatory bowel disease (IBD) patients by limiting their access to medical services due to restrictions and the reorganization of the healthcare systems, which affects their quality of life (QoL). We aimed to assess the impact of the COVID-19 pandemic on the QoL of patients with IBD. Materials and Methods: We conducted a descriptive observational study, which included 90 adult patients diagnosed with IBD. The study sample consisted of two subgroups: a retrospective-pre-pandemic group (group A) and a prospective-pandemic group (group B). Group A included 45 IBD patients who were evaluated in 2018. Group B included 45 patients with confirmed diagnosis of IBD, evaluated between June and December 2021—the period of the COVID-19 pandemic (prospective), consecutively recruited. All the patients filled in a QoL assessment questionnaire—IBDQ-32. Subsequently, the two samples were comparatively assessed. Results: The average values of the IBDQ scores were significantly lower in 2021 compared to those recorded in 2018: 145.56 vs. 128.3 (p < 0.05). We also we found significant differences between the subscores: IBDQ1 (p = 0.043), IBDQ2 (p = 0.034), IBDQ3 (p = 0.045), IBDQ4 (p = 0.025). Conclusions: IBDQ scores were significantly lower in 2021 compared to 2018 (p < 0.05), showing that during the COVID-19 pandemic, patients with IBD had a more influenced QoL.

show abstract

Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea

et al. 2023

View full text Add to dashboard Cite

ObjectiveImmune-mediated inflammatory disease (IMID) is associated with an increased risk of mortality. It is unclear whether the higher mortality is attributable to the IMIDs themselves or to the higher prevalence of comorbidities in IMIDs. We aimed to investigate whether IMIDs per se confer a higher risk of mortality.MethodsFrom the Korean National Health Insurance Service-National Sample Cohort database, this population-based cohort study included 25,736 patients newly diagnosed with IMIDs between January 2007 and December 2017, and 128,680 individuals without IMIDs who were matched for age, sex, income, hypertension, type 2 diabetes, dyslipidemia, and the Charlson comorbidity index. All individuals were retrospectively observed through December 31, 2019. The outcomes included all-cause and cause-specific mortalities. Adjustments for age, sex, and comorbidities were performed using multivariable Cox proportional hazard regression analyses, and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for the outcomes were estimated.ResultsThe adjusted risk of all-cause mortality was significantly lower in patients with IMIDs than that in those without (aHR, 0.890; 95% CI, 0.841–0.942). Regarding cause-specific mortality, cancer-specific (aHR, 0.788; 95% CI, 0.712–0.872) and cardiovascular disease-specific (aHR, 0.798; 95% CI, 0.701–0.908) mortalities were the two causes of death that showed significantly lower risks in patients with IMIDs. A similar trend was observed when organ based IMIDs were analyzed separately (i.e., gut, joint, and skin IMIDs).ConclusionAfter adjusting for comorbidities, IMIDs were associated with a lower risk of all-cause mortality compared to those without IMIDs. This was attributable to the lower risks of cancer-and cardiovascular disease-specific mortalities.

show abstract

Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study

Cited by 3 publications

References 29 publications

Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis

Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis

Impact of COVID-19 Pandemic on the Quality of Life of IBD Patients

Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea

Contact Info

Product

Resources

About